Instructions for Ovestin (Estriol)
Features
Method of use Vaginal, Oral
Pack quantity 1 pc
Maximum storage temperature allowed, °C 30 °C
Best before date 36M
Storage Conditions In a dry place
Release form Cream
Weight 15g
Country of manufacture Ireland
Vacation Policy Prescription
Active substance Estriol
Scope Gynecology
Pharmacological group G03CA04 Estriol
Registered as Medicinal agent
Description Estriol:
The tablets are white in colour, round, flat, 6 mm in diameter, chamfered and risque, with the engraving "DG" above the risk and the number "8" - under the risk, on one side of the tablet.
1 tab.
estriol 2 mg
Auxiliary substances: silicon dioxide colloidal - 0.75 mg, potato starch - 10 mg, magnesium stearate - 0.5 mg, povidone - 1 mg, lactose monohydrate - up to 100 mg (about 87.75 mg), water distilled - q.s. (removed during production).
30 pcs - blister packs (1) - cardboard packs.
vaginal supp. 0.5 mg: 15 pcs
Rectal suppositories in the form of torpedoes in white to light cream; the surface and the longitudinal section are homogeneous.
1 sp.
estriol 0.5 mg
Auxiliary substances: vitepsol S58 - 2.4995
5 pcs. - box-type contour (3) packages - cardboard packs.
vaginal cream 1 mg/1 g: 15 g ac tube with applicator
Description
The cream is vaginal in the form of a homogeneous mass of creamy consistency, from white to almost white, with a specific smell.
1g
estriol 1 mg
Auxiliary substances: octyldodecanol - 50 mg, cetilpalmitate - 15 mg, glycerol - 120 mg, cetyl alcohol - 36.7 mg, stearyl alcohol - 88.4 mg, polysorbate 60 - 32.4 mg, sorbitana stearate - 7.6 mg, lactic acid - 4 mg, chlorhexidine dihydrochloride - 0.1 mg, sodium hydroxide - up to pH 4, water purified - up to 1000 mg.
15 g - aluminium tubes (1) complete with applicator - cardboard packs.
Clinical-pharmacological groups / Group affiliation
Estrogen preparation
Active substance
estriol
Pharmacotherapy group
Estrogen
Storage Conditions:
The drug Ovestin should be stored in a place protected from light, inaccessible to children at a temperature of 2° from 30°C.
Best before date
Shelf life is 5 years. Do not use after expiry date specified on package.
Testimony Estriol:
- Atrophic lining of the lower urinary tract caused by estrogenic insufficiency, in particular for the treatment of symptoms
- such as vaginal dyspareunia, dryness and itching,
- to prevent recurrent infections of the vagina and lower urinary tract;
- For the treatment of urinary disorders (e.g., increased frequency, dizuria) and moderate urinary incontinence;
- pre- and post-operative treatment for vaginal surgery in the postmenopausal period;
- climacteric disorders, such as tidal,
- night sweats;
- as a diagnostic aid for the production of an atrophic picture of cervical swab;
- Infertility caused by cervical factor.
vaginal cream, suppository indication to application:
- Hormone replacement therapy (SGT) for the treatment of low urinary tract atrophy associated with estrogenic failure in postmenopausal women;
- Pre- and post-operative treatment of postmenopausal women with vaginal access surgery;
- as a diagnostic aid for the production of an atrophic picture of cervical smear.
Method of use, course and dosage Estriol:
Cream and suppositories vaginal
Ovestin® cream should be injected into the vagina with a calibrated applicator at bedtime.
1 application (applicator filled to the ring mark) contains 0.5 g of cream, which corresponds to 0.5 mg of estriol.
In the treatment of lower urinary tract atrophy, 1 application/day during the first weeks (maximum 4 weeks) followed by gradual reduction of the dose based on symptom relief until a maintenance dose is reached (i.e. 1 administration 2 times per week).
For pre- and post-operative treatment of women in postmenopausal period with vaginal surgery - 1 application/day for 2 weeks before surgery; 1 application 2 times a week for 2 weeks after surgery.
For diagnostic purposes, in the case of unclear results of the cervical cytological examination, 1 application is performed every day for a week before the next smear.
If the dose is missed, the missed dose should be administered on the same day as the patient remembers it (the dose should not be administered 2 times/day). Subsequently, the application is carried out in accordance with the usual dosing schedule.
The lowest effective dose shall be administered for the shortest period of time at the beginning or continuation of treatment of the climacteric symptoms.
In women who do not receive GST or women who are transferred from continuous oral combination GST, Ovestin® treatment can be started any day. Women who switch from a cyclical GST regimen should start treatment with Ovestin® 1 week after the withdrawal of GST.
Pill Application:
The drug Ovestin is applied internally. Daily dose should not exceed 8 mg. Daily dose should be taken in one dose.
The tablets are taken with water, preferably at the same time of day.
Application for kidney disorders
Estrogens can cause fluid retention, so patients with kidney failure should be closely monitored by a doctor.
Use in liver disorders
The use of the preparation is contraindicated in the case of acute liver diseases or liver diseases in the history, after which the liver function indices did not return to normal.
With caution, you should prescribe the drug Ovestin for severe liver diseases (for example, adenoma).
Terms of Sale
The drug Ovestin is prescription.
Nosology (ICD codes)
N34
Urethritis and urethral syndrome
N95.1
Menopause and Menopause in Women
N95.2
Postmenopausal atrophic vaginitis
N95.3
Conditions associated with artificially induced menopause
N97
Female infertility
Z03
Medical observation and evaluation in the case of suspected disease or pathological condition
Z51.4
Preparatory procedures for follow-up treatment or examination not classified elsewhere
